ArticleBMC geriatrics2025
Evaluation of the utility of different laboratory test-related sarcopenia indices as predictors of lung cancer mortality.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesWe evaluated the utility of routine laboratory test-related sarcopenia indices as predictors of mortality in older patients with primary lung cancer undergoing the first chemotherapy course.
designRetrospective cohort study.
settingWest China Hospital, Chengdu, China.
participantsThis study enrolled primary lung cancer patients ≥ 60 years of age undergoing their first chemotherapy course. MEASUREMENTS: Data on individual patients were obtained from the medical records, while information on survival outcomes was gathered through telephone-based follow-up or local government databases. Using available routine hematological and biochemical test results, this study calculated three sarcopenia-related indices for each patient. These indices included the AST/ALT ratio, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). We assessed the relationships between these indices and death using Cox proportional hazards models.
resultsThe study included 926 primary lung cancer patients (71.5% male; median age: 65 years) who underwent their first course of chemotherapy. During the follow-up period (median: 28 months), 563 patients (60.8%) died. In the overall population, there was a significantly higher likelihood of all-cause mortality in patients with an NLR ≥ 2.88 (HR = 1.60, 95% CI = 1.36-1.90, P < 0.001) or a PLR ≥ 125.11 (HR = 1.39, 95% CI = 1.17-1.64, P < 0.001) compared to those with values below these thresholds. However, after adjustment for potential confounding factors, no association was found between NLR or PLR and mortality. After stratification by sex, it was found that both NLR and PLR values were associated with an increased risk of mortality among women (NLR: HR = 2.1, P < 0.001; PLR: HR = 2.42, P < 0.001).
conclusionsNLR and PLR, are indicators of sarcopenia and can be easily derived from routine laboratory testing data. These indices can significantly predict mortality in older female patients with primary lung cancer at the start of chemotherapy. Therefore, there is potential practical value in using these indices for assessing patient risk prior to chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.